Home/Editorial Board

Editorial Board

BMJ Oncology Editorial Board members have agreed and adhere to the BMJ Editor Roles and Responsibilities guidelines; including our Editor policy on competing interests. Meet the editorial team.


Ananya Choudhury, MA (Cantab), PhD, MRCP, FRCR Chair and Honorary Consultant in Clinical Oncology Group Leader Translational Radiobiology The Christie NHS Foundation Trust Manchester, United Kingdom Photo of Ananya Choudhury Declaration of Interests, see here
Professor Choudhury is Chair and Honorary Consultant in Clinical Oncology. She joined The Christie in 2008 specializing in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. She is clinical lead for advanced radiotherapy including the MRLinac project and is co-Group Leader of The Translational Radiobiology Group within the Division of Cancer Sciences. Professor Choudhury currently undertakes research which aims to optimize and personalize radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimizing side effects and predictive biomarkers to determine which patients benefit from different treatments. Professor Choudhury formerly served as Editor-In-Chief of Clinical Oncology, the official journal of The Royal College of Radiologists. In addition, Professor Choudhury was a  Senior Editor for Genito-urinary cancers for the International Journal of Radiation Oncology • Biology • Physics (The Red Journal). Although coming from a radiotherapy specialist area, Professor Choudhury is passionate about all aspects of general oncology. Editorially, Professor Choudhury advocates equality and diversity in research and publication and promotes partnership with patients and the public.

Clinical Editor

Kristoffer Stewart BMJ London, United Kingdom Photo of Kristoffer Stewart
Kristoffer is a UK-trained pharmacist working in education and publishing. His education interest has focused on general practice and early career practitioners. Kristoffer has worked with BMJ Best Practice, BMJ Learning and The Pharmaceutical Journal. Kristoffer is excited to work on BMJ Oncology and to develop a dynamic cross-disciplinary editorial board to attract the best research, reviews and editorials.

Editorial Board Members

Bishal Gyawali Queen's University Ontario, Canada Photo of Bishal Gyawali
Bishal Gyawali, MD, PhD is a medical oncologist and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada. He did his cancer policy fellowship at Harvard Medical School and previously served as a medical consultant for the not-for-profit Anticancer Fund, before joining Queen’s. His clinical expertise is across multiple adult solid tumors, with special focus on GI, GU and breast malignancies. Dr. Gyawali is an expert for the WHO Drug Advisory Panel. He is a member of the WHO Essential Medicines List Committee for cancer drugs, ESMO-Magnitude of Clinical Benefit Scale and ESMO Global Policy committees, and ASCO-Health Equity and Outcomes Committee. Research focus: Dr. Gyawali’s areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, cancer care disparities, and global oncology. He introduced the term “cancer groundshot” and chaired a session on the same at ASCO 2022. His interviews and studies have been reported in several influential media (e.g. CNN, NPR, Washington Post, STAT News etc). ORICD: https://orcid.org/0000-0001-7444-8594
Laure Marignol Trinity College Dublin, Ireland Photo of Laure Marignol
Laure Marignol is an associate professor and the Head of Discipline of Radiation Therapy at Trinity College Dublin, Ireland. She leads an internationally recognised radiobiology laboratory. Laure is an active member within the radiobiology international community. She holds a leadership position within the Irish Radiation Research Society and sits on the Radiobiology Committee of the European Society for Radiotherapy and Oncology (ESTRO). She serves as specialist examiner for Royal College of Radiologists in the UK. Research focus: Dr Marignol’s lab aims to generate new prognostic algorithms that detect patients at high risk of failure following radiation therapy, and design new therapeutic options that prevent tumour regrowth after radiotherapy. She has published works aimed at addressing the international challenge of growing solutions for the optimal destruction of cancer cells. ORICD: https://orcid.org/0000-0002-2680-6200
Richard Simcock University Hospital Sussex Sussex, UK Photo of Richard Simcock
Richard Simcock MRCPI FRCR is a Consultant Clinical Oncologist at University Hospital Sussex NHS Trust and Honorary Professor at Brighton and Sussex Medical Schools. He is Chief Medical Officer at Macmillan Cancer Support where he co-leads the Centre of Clinical Expertise. Research focus: Research and training on communication, shared decision making. Free open access medical education via social media. Interested in improving the care of the older adult with cancer including the assessment and management of frailty and multimorbidity. Planning and delivery of personalised care and innovative workforce solutions are current preoccupations ORCID: https://orcid.org/0000-0002-9828-4114
Yat Man Tsang Princess Margaret Cancer Center Ontario, Canada Photo of Tsang Yat
Currently, Yat Man Tsang is employed as the Director of Radiation Therapy within the Radiation Medicine Program at the Princess Margaret Cancer Center under University Health Network in Canada. He is a senior member of the UK National Institute of Health Research (NIHR) Radiotherapy Trials QA Group with experience in designing and implementing quality assurance programmes for NIHR clinical trials. Being the Chair of the European society for radiotherapy and oncology Radiation Therapist Committee, Yat is accountable for leading and organising international radiotherapy specific projects Research focus: Radiotherapy trial quality assurance, ultra-hypofractionated/ stereotactic radiotherapy treatment outcomes, and strategies to future-proofing radiation therapist practice.
Jeena Ackroyd Calderdale Royal Hospital West Yorkshire, UK Photo of Jeena Ackroyd
Jeena Ackroyd is a Consultant in Palliative Medicine in Calderdale West Yorkshire. She has a Masters in the Ethics of Cancer and Palliative care and is a member of the local clinical ethics committee and nationally is the palliative care representative for the NICE metastatic spinal cord compression updated guidelines committee. Research focus: Complex decision making in cancer patients, especially around end of life care. Supportive interventions for haematology patients and mentoring for clinicians.
Vedang Murthy Tata Memorial Centre Mumbai, India Photo of Vedang Murthy
Vedang Murthy is a Professor of Radiation Oncology at Tata Memorial Centre, Mumbai. Dr. Murthy also trained at The Royal Marsden NHS Foundation Hospital, London and undertook a Diploma in Epidemiology and Biostatistics from the London School of Hygiene and Tropical Medicine. Dr Murthy is the Convenor of Uro Oncology Disease Management group at the Tata Memorial Hospital and currently running investigator-initiated randomised trials in prostate and bladder cancer. Research focus: Stereotactic Body Radiation Therapy and Pelvic Radiation Therapy for high risk prostate cancer, prostate-specific membrane antigen positron emission tomography (PSMA PET) in Prostate cancer, bladder preservation and adjuvant radiotherapy in bladder cancer and radiotherapy in seminoma and advanced penile cancers.
Eliana Vasquez Osorio University of Manchester Manchester, UK Photo of Eliana Vasquez Osorio
Dr Vasquez Osorio studied computer sciences at the Universidad EAFIT, Medellin Colombia. She then did her PhD at Erasmus University in Rotterdam, The Netherlands and is currently a senior research fellow at the University of Manchester. Research focus: Her areas of expertise include image processing, non-rigid image registration, computational geometry, deformation modelling and treatment outcome modelling. She also works with artificial intelligence techniques to solve radiotherapy problems.
Miriam Mutebi Aga Khan University Nairobi, Kenya Photo of Miriam Mutebi
Dr. Miriam Mutebi is a Consultant Breast Surgical Oncologist and Assistant Professor of Surgery at the Aga Khan University in Nairobi, Kenya. She is also a clinical epidemiologist and health systems researcher. She is the President Elect of the African Organization for Research and Training in Cancer (AORTIC), the immediate past president for the Kenya Society of Hematology and Oncology (KESHO) and on the board of directors of the Union for International Cancer Control (UICC). She is the Co-chair of the National Cancer Taskforce in Kenya, Chair of the Commonwealth Taskforce for the elimination of Cervical Cancer and a commissioner on five Lancet commissions including Breast Cancer, Women and Cancer and Cancer in sub-Saharan Africa etc. Research focus: Her focus is on on understanding barriers to access for women with cancers in Africa and in designing interventions to mitigate those barriers, health systems strengthening, health policy and cancer disparities.
Melvin Lee Kiang Chua National Cancer Centre Singapore Singapore Photograph of Melvin Chua
Dr Chua, MBBS, FRCR, PhD, FAMS is a Clinician-Scientist at the National Cancer Centre Singapore (NCCS) and Duke-NUS Medical School, and Principal Investigator of the Precision Radiotherapeutics and Oncology Programme, Division of Medical Sciences, supported by the NMRC Clinician-Scientist Award. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology, and Director of the Data and Computational Science Core at the NCCS. Research focus: His research focuses on the development of Phase II-III clinical trials in nasopharyngeal (NPC) and prostate cancers. He also runs a laboratory that is involved in data science and omics analytics that help with therapeutic and biomarker discovery for these cancer types.
Massimo Di Maio University of Turin Turin, Italy Photo of Massimi Di Maio
Massimo Di Maio is a professor of Medical Oncology at the Department of Oncology, University of Turin, Italy. Professor Di Maio has a documented experience in the field of academic, non-profit research. From 2000 to 2006 and from 2008 to 2014 he worked at the Clinical Trials Unit of the National Cancer Institute “G.Pascale” Foundation, in Naples, Italy, where he was involved in the planning, conducting and analysis of many clinical trials. During his scientific career, he has authored nearly 400 publications in international peer-reviewed journals and has been invited as speaker at many national and international meetings. Research focus: His main areas of interest are the methodology of clinical trials in oncology, the conduction of meta-analyses based on individual patients’ data, the analysis of health-related quality of life and the role of patient-reported ORCID: https://orcid.org/0000-0001-8906-3785
John Liao University of Washington – Fred Hutchinson Cancer Center Seattle, United States
John Liao is Associate Professor in the Division of Gynecologic Oncology at the University of Washington – Fred Hutchinson Cancer Center. Research focus: Dr. Liao leads a clinical and translational research program studying immunotherapies for gynecologic cancers. His research focuses on the development of novel vaccines, cellular therapies and other immunotherapies and the identification of biomarkers that predict response to immunotherapy. He serves as principal investigator of phase 1 and phase 2 clinical trials and directs a translational laboratory that studies novel therapies in preclinical models and profiles the immune response of patients receiving investigational immunotherapies.
Claudia Parisi Gustave Roussy Institute Villejuif, France Photo of Claudia Parisi
Claudia Parisi is a Medical Oncologist currently employed at the Department of Early Drug Development (DITEP) of Gustave Roussy Institute (Villejuif, France). Dr Parisi is also a PhD student in translational medicine and oncology at the University of Rome, La Sapienza. Research focus: Dr Parisi’s main areas of interest are lung cancer genomics, investigational cancer therapeutics in thoracic malignancies, implementation of digital technology to build personalized pathway of care. Her publications are mainly focused on Non-Small Cell Lung Cancer (NSCLC) treatment and novel molecular biomarkers. ORICD: https://orcid.org/0000-0002-6259-8234
Rachel Simoes Pimenta Riechelmann A. C. Camargo Cancer Center São Paulo, Brazil Photo of Rachel Simoes Pimenta Riechelm
Professor Rachel Riechelmann is a medical oncologist and clinical scientist. She is currently Director of the Clinical Oncology Department, A. C. Camargo Cancer Center, Sao Paulo, Brasil and also serves as the President of the Brazilian GI Tumors Group (GTG). She has 145 publications in peer-reviewed journals, including national treatment guidelines for GI cancers, 2023 ASCO Educational Book chapter on therapeutic sequencing in NET and is editor of the book Methods and Biostatistics in Oncology: Understanding Clinical Research as an Applied Tool, Springer 2018. Professor Riechelmann is member of ESMO Scientific Committees, and the European Society of Neuroendocrine Tumors Advisory Board. She is also actively involved in mentoring and teaching young oncologists, including the founding of the 1st NET fellowship in Brazil. Research focus: Her focus is colorectal cancer, anal cancers and neuroendocrine tumors (NET).
Shereen Nabhani-Gebara Kingston University London, UK Photo of Shereen Nabhani-Gebara
Dr Nabhani-Gebara is an Associate Professor in Oncology Pharmacy at Kingston University London. She has a doctorate in pharmacy with postgraduate qualifications and specialisation in oncology. She has a global view of cancer care as she has trained and worked on three different continents. She sits on the British Oncology Pharmacy Association (BOPA) executive board, and is the founding chair of the BOPA Equality, Diversity and Inclusion subcommittee and the chair of its research committee. Research focus: Evolving cancer services to optimise early detection and follow up care, technology enabled care (including artificial intelligence), and optimising the quality of cancer care through equity and inclusion.
Haryana Dhillon The University of Sydney Sydney, Australia Photo of Haryana Dhillon
Associate Professor Haryana Dhillon (BSc MA PhD) is a Senior Research Fellow, who co-leads the Survivorship Research Group at the University of Sydney. They chair the Scientific Advisory Committee of the Psycho-Oncology Cooperative Research Group. Haryana has more than 25 years experience in cancer clinical research across a range of investigator-initiated cancer clinical trials. Research focus: Haryana’s research interests are broad and encompass cancer survivorship, health literacy, interventions for survivorship, symptom management, and psycho-oncology. Haryana is passionate about rigour in research, practical solutions to tricky problems, and doing what she can to help humans make it to the 22 nd century.
Rick Bangs Cancer Research Advocacy Leadership New York, United States Photo of Rick Bangs
Rick Bangs, MBA/PMP, is a bladder and prostate cancer survivor and has worked as a patient advocate in a variety of roles, including research advocacy, government lobbying, educational support, support groups, one-on-one support, and fundraising. He serves Chair of the Southwest Oncology Group (SWOG) Patient Advocate Committee, a member of the SWOG Executive Advisory Committee and Committee Chair Committee, the SWOG Bladder Cancer Patient Advocate emeritus, the Bladder and Penile Cancer Patient Advocate for the National Comprehensive Cancer Network (NCCN), as one of three NCI Cancer Care Delivery Scientific Steering Committee Patient Advocates, and as a Patient Advocate on ASCO and AUA Guideline Panels. Research focus: Rick’s interests include clinical trials, engagement of patient advocates in research, patient-centered outcomes, and diversity, equity, and inclusion in clinical trial workforce, studies, and participation.
Ollie Minton University Hospitals Sussex Sussex, UK Photo of Ollie Minton
Ollie Minton is the macmillan clinical lead in palliative medicine based at University Hospitals Sussex . He is also the national clinical advisor to Macmillan cancer support for end of life care. Ollie’s role is to provide clinical leadership to the team which advises other members of the hospital on end of life care including their families and friends as well as develop an evidence base for cancer services from diagnosis onwards including survivorship. Research focus: He is part of a research active team that continually looks at quality and service improvement and education of staff and undergraduate students of all healthcare disciplines. Ollie’s PhD and subsequent work focuses on fatigue and a broader interest in the biological basis of cancer symptoms including Patient Reported Outcome Measures (PROMs). Ollie is also interested in acute cancer care and supportive oncology to provide a seamless service to all cancer patients. Research gate ID  Ollie Minton (researchgate.net) ORCID: https://orcid.org/0000-0002-4258-8995
Ni Li National Cancer Center/National Clinical Research Center for Cancer Beijing, China Photo of Ni Li
Professor Ni Li currently serves as the Deputy Director of the Office of Cancer Screening at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Research focus: Professor Ni Li is primarily dedicated to public health research, with a specific focus on cancer screening and early diagnosis. Her work encompasses various aspects such as conducting large-scale cancer screening studies, identifying high-risk populations for cancer.
Karima Oualla University Sidi Mohamed Ben Abdellah Fez, Morocco Photo of Karima Oualla
Karima Oualla ,MD, MSc is a medical oncologist and an associate professor at the University Sidi Mohamed Ben Abdellah in Morocco. Dr Oualla completed her medical training at University Sidi Mohamed Ben Abdellah prior to practicing as a Medical Oncologist at Hassan II University Hospital. She also earned a degree in epidemiology and clinical research from University Sidi Mohamed Ben Abdellah then joined Institut Jules Bordet in Brussels, Belgium, as an assistant doctor (2012–2013). Dr Oualla serves on the leadership Council of the Global Society of Rare Genitourinary Tumors (GSRGT), and the scientific committee of the International Bladder Cancer Group (IBCG). She is a member of ESMO, the American Society of Clinical Oncology (ASCO), the European School of Oncology (ESO). Research focus: Dr Oualla’s main areas of interest are in therapeutic approaches to cancers using immune checkpoint inhibitors and the use of novel therapeutic strategies in the treatment of triple negative breast cancer.

Statistical Editorial Board

Allan Hackshaw University College London Cancer Research UK & UCL Cancer Trials Centre London, UK Photo of Alan Hackshaw
Allan Hackshaw is Professor of Epidemiology & Medical Statistics at University College London, and Director of the Cancer Research UK & UCL Cancer Trials Centre, one of the largest cancer trials units in the UK. Previously, he was at the Wolfson Institute of Environmental and Preventive Medicine, Barts, London. Research focus: He has >30 years’ experience in the design, conduct and interpretation of phase I-III clinical trials, observational studies, real world data studies and systematic reviews, in a variety of disease areas; including cancer treatments and diagnosis, adult and prenatal screening, cardiovascular disease, and tobacco and health. He has worked in several cancer types (notably lung, thyroid, breast and gynaecological) and all types of interventions (systematic therapies including targeted and immunotherapies, radiotherapy, surgery, and combinations of them). He has published more than 200 journal articles and book chapters, and sole or first author of four textbooks, including two on clinical trials. He delivers modules on evidence-based medicine and clinical trials for postgraduate courses at UCL and the London School of Economics. ORCID: https://orcid.org/0000-0002-5570-5070
Amy Kirkwood University College London London, UK Photo of Amy Kirkwood
Amy Kirkwood is an Associate Professor in Medical Statistics at the CRUK and UCL Cancer Trials Centre. She was worked in cancer trials for almost 15 years, including all phases and covering a range of interventions. Research focus: She specialises in haematological malignancy trials, with a particular interest in Hodgkin’s lymphoma and acute lymphoblastic leukaemia.
Andre Lopes University College London, UK Photo of Andre Lopes
Andre Lopes is an Associate Professor in Medical Statistics at the CRUK & UCL Cancer Trials Centre. Research focus: His research interests are focused on the design of early and late phase cancer clinical trials, in particular gastrointestinal, sarcoma, and CAR-T cell therapies. He also has special interests in health outcomes in cancer research including health-related quality of life and disease stabilisation, and joint survival and longitudinal analyses.
Nicholas Counsell University College London, UK Photo of Nicholas Counsell
Nicholas Counsell is a Principal Statistician and Associate Professor (Medical Statistics) at the Cancer Research UK and University College London Cancer Trials Centre. Research focus: Nicholas has more than 15 years’ experience as a medical statistician, and he works on the design, conduct, analysis and reporting of Phase I-III clinical trials in a variety of different tumour groups, in particular lung and gynaecological cancer. He also has an interest in cancer screening & early detection, systematic reviews and prognostic modelling.

Social Media Editor

Benjamin Mazer Johns Hopkins University Baltimore, United States Photo of Benjamin Mazer
Dr. Benjamin Mazer is an assistant professor of pathology at Johns Hopkins University, where he practises general surgical pathology and gastrointestinal pathology. He received his undergraduate degree from Swarthmore College, followed by an MD and MBA from the University of Rochester. He completed residency training in anatomic and clinical pathology, as well as fellowship training in gastrointestinal and liver pathology, at Yale. Research focus: His academic interests include cancer screening and overdiagnosis, evidence-based medicine, and health policy. Dr. Mazer is also a freelance journalist writing about medical topics and controversies for the public.

Junior Social Media Editor

Holly Egan The University of Manchester Manchester, UK Photo of Holly Egan
Holly is a medical student at The University of Manchester with a keen interest in Clinical Oncology and research within all fields of Oncology. She is also a Biomedical Sciences Graduate from Newcastle University. Holly has experience in conducting and presenting research internationally, and has her own social media presence with more than 7000 followers.

Publishing Team

Publisher: Shannon Lewis Head of Portfolio: Kathleen Lyons